Completed OBSERVATIONAL NCT00809731

Observational Study to Evaluate Efficacy and Remission Status for Schizophrenia Patients Under Atypical Treatment (QTP NIS)

A Naturalistic Observational Study to Evaluate Efficacy of 2nd-generation Antipsychotics and Remission Status for Patients With Schizophrenia / Schizoaffective Disorder

Sponsor: AstraZeneca

Conditions Schizophrenia

Updated 7 times since 2017 Last updated: Dec 8, 2010 Started: Dec 31, 2008 Primary completion: Sep 30, 2010 Completion: Sep 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Schizophrenia, this trial is completed. The trial is conducted by AstraZeneca and has accumulated 7 data snapshots since 2008. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed
Sep 2024 — Sep 2025 [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed

▶ Show 2 earlier versions

Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None
Jan 2017 — Apr 2018 [monthly]

Completed NA

First recorded

Dec 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca

Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Changhua, Taiwan , Changhua-Lugang, Taiwan , Chiayi City, Taiwan , Kaohsiung-Niosong, Taiwan , Kaohsiung-Sanmin, Taiwan , Kaohsiung-Yanchao, Taiwan , Keelung, Taiwan , Miaoli, Taiwan , Miaoli-Toufen, Taiwan , Taichung-Beitun, Taiwan and 7 more locations